In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

Speakers from Almirall, AstraZeneca, Bayer, BioNTech, Glenmark, and GSK share innovative approaches to drive commercial excellence BARCELONA, Spain, Oct. 29, 2024 /PRNewswire/ -- Veeva ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

PFG Investments LLC lifted its position in GSK plc (NYSE:GSK – Free Report) by 8.5% in the 3rd quarter, Holdings Channel.com ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...